GET THE APP

Tumor-specifi c Anergy vs Global immunosupression in immunity to brain tumors
Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

Tumor-specifi c Anergy vs Global immunosupression in immunity to brain tumors


International Conference & Exhibition on Cell Science & Stem Cell Research

29 Nov - 1 Dec 2011 Philadelphia Airport Marriott, USA

Valentin Shichkin and Dmitry Krasnenkov

Accepted Abstracts: J Cell Sci Ther

Abstract :

Induction of immune response to brain tumors is limited by blood brain barrier that bounds access of na´ve T cells to the brain as well as failure of brain environment to activate infi ltrating T cells inducing the state of anergy. Anergic T cells are neither deleted nor altered with regard to levels of TCR and co-receptor molecules, but are refractory to the recalling antigenic stimulus. A number of studies also support the hypothesis that tumors evade immunological rejection inducing regulatory CD4 + CD25 + T cells and state of global immunosupression producing TGF-β, IL-10, PG-E2 et al. In this study, mouse B-cell lymphoma engineered to express hemagglutinin (HA) antigen was used as a brain tumor model in which HA-specifi c CD4 + T cells transferred to syngeneic recipients were monitored during the brain tumor progression. T cells demonstrated the activation already on day 2 aft er the adoptive transfer and became anergic to day 16. Signs of systemic immunosupression were observed in mice with massive brain tumors and sick symptoms at the late stage of the brain tumor progression. Th e process is accompanied by very fast reduction of spleen and lymph nodes in symptomatic mice assuming the metabolic stress and corticosteroid emission that dramatically damages the lymphoid organs. However, even at the late stage there still are remaining the tumor-specifi c T-cells that can be restimulated in vitro with HA antigen. Th us, our data suggest at the reasonable conditions the immune response against advanced brain tumors may be reversible at least for some high-resistant CD4 + T cells

Biography :

Prof. Shichkin has got his MS (1981) in Biology from Nizhny Novgorod State University (Russia), PhD (1986) and DSc (1991) in Immunology from Institute of Immunology (Moscow). He then improved his expertise in Immunology in the USA (1998-2003) at the National Cancer Institute ? NIH, University of Cincinnati and John Hopkins University. He held academic research positions as a Senior Scientist, Principal Scientist and Laboratory Chief. He is now a professor of Immunology at the University ?Ukraine? and Taras Shevchenko National University in Kyiv (Ukraine). He is author more 80 publications in fi elds of immunobiology, hybridoma technology and cancer immunology

Top